Clinical trial · Interventional
Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma.
Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma, a Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Organisational difficulties
Summary
Brief summary (as posted)
The 18-kDa translocator protein (TSPO) is a mitochondrial protein that is weakly expressed in the healthy brain. However, there is an increase in the expression of TSPO in glial tumors. It is even associated with a higher malignancy and a shorter survival of patients. Among the different TSPO ligands, the most commonly used tracers in PET imaging are \[18F\]DPA-714 and 18F-GE180. We hypothesize that \[18F\]DPA-714 PET could improve the current performance for tumor grade definition in vivo, which is a major issue for the therapeutic management of gliomas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F]DPA-714 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- [18F]DPA-714 PET
- interventionNames
- Drug: [18F]DPA-714
Primary outcomes (1)
- measure
- Diagnostic performances of [18F]DPA-714 PET for glioma grading obtained by stereotactic biopsies of glioma
- timeFrame
- [18F]DPA-714 PET performed up to 30 days before brain surgery
- description
- Sensitivity and specificity of \[18F\]DPA-714 PET using anatomopathological assessment of biopsies as gold standard
Secondary outcomes (2)
- measure
- Comparison of [18F]DPA-714 PET quantitative parameters with anatomopathological assessment of the surgery specimen
- timeFrame
- [18F]DPA-714 PET performed up to 30 days before brain surgery
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age greater than or equal to 18 years * Suspicion of an operable diffuse glioma * Written informed consent (signed) * Affiliated or beneficiary of a social security plan Exclusion Criteria: * Suspicion of grade I glioma * Surgical urgency (less than 8 days between the suspected diagnosis and surgery) * Pregnant or breastfeeding woman * Persons deprived of liberty or under guardianship * Impossibility to undergo the medical follow-up of the trial for geographical, social or psychological reasons
References
Publications (0)
Data not yet available